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PSORIASIS VULGARIS IN SPANISH PATIENTS
Mirada A1, Lecha M2, Barnés E3, López JS4
1Laboratorios Isdin, Barcelona, Spain; 2H. Clínic i Provincial de
Barcelona, Barcelona, Spain; 3Pharma-Consult, Barcelona, Spain;
4Pharma-Consult, Barcelona, Spain
OBJECTIVES: To analyse the effectivity and safety of
tacalcitol in real daily conditions. METHODS: An epi-
demiological, observational, prospective and multicenter
study of a cohort of patients with mild to moderate Pso-
riasis vulgaris has been performed. Treatment with tacal-
citol ointment (4mg/g) was prescribed. Anthropometric
and demographic characteristics of patients were re-
corded in addition to percentage of affected area and pre-
vious and current treatments. A lesion was selected as
target for evaluation, of symptoms (erythema, desqua-
mation and thickness) by a scale from 0 (absent) to 4
(maximum intensity of symptom). At follow-up (30 and
60 days) symptomatology and appearance of adverse
events were evaluated. Psoriasis Area Severity Index
(PASI) was calculated. RESULTS: Eight hundred twenty-
one patients with mild to moderate Psoriasis vulgaris,
(45.67% were men and 45.33% were women, mean age
43.59 ± 15,48 years) were included. After 2 months of
treatment, patients showed a decrease of mean percent-
age of affected area of 7.83 ± 12.3 (from 15.97% ±
16.02% to 8.14 ± 10.59). PASI decreased from 10.11 ±
7.89 to 3.00 ± 3.79 (p < 0.01). Percentage of patients
without symptoms increased up to 85.44% for erythema,
93.11% for desquamation and 96.16% for thickness. Six
adverse events were reported (1% of sample). Seventy-
eight percent of investigators and 80% of patients 
evaluated effectivity of treatment as satisfactory. CON-
CLUSIONS: Tacalcitol was effective in symptomatic
treatment of psoriasis. Treatment achieved improvement
on affected area and intensity of symptoms as well. Excel-
lent tolerability of tacalcitol was corroborated by the low
rate of adverse events reported.
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Brun—Strang C1,Taïeb A2
1Novartis-Pharma, Rueil-Malmaison, France; 2Hôpital St André,
Bordeaux, France
OBJECTIVE: To evaluate the management and socio-
economic consequences of AD on patients and parents of
children with AD in France. METHODS: Retrospective
crossectional study in a representative national sample of
patients suffering from AD has been conducted between
March and June 2002. One hundred children and 90
adults have been recruited from a representative panel of
4012 individuals of the general population. Data was col-
lected on aspects of the disease, medical resource use and
Quality of Life (QoL). RESULTS: On average, the mean
time spent with AD during the last year was 131 days;
26% of patients reported having symptomatic AD all the
time, the other patients had 5.5 ﬂares on average. Mean
duration of the last ﬂare in the overall sample was 21
days. Ninety percent of the patients consulted a physician
during the last year for their AD. Sixty-two percent of
adults had usually seen a general practitioner (GP) and/or
a dermatologist (57%). Fourty-one percent of adults and
42% of children had seen a GP exclusively. None of the
patients interviewed were hospitalized for AD during the
last 12 months. We estimated the annual medical and
non-medical cost of AD in France at €128 million per
year, physician consultations accounting for 59% of this
cost. AD impairs signiﬁcantly the patients and parents
QoL. Adults declared having no relieve from it (40%),
being worried about their appearance (36%), ﬁnding it
hard to relax (33%), having no self-conﬁdence (24%).
Parents reported having no control over the disease
(53%), are worried about the future of their children
(17%) and 13% said AD created much tension in the
family. CONCLUSION: This unprecedented study shows
that AD signs and symptoms affect patients for one-third
of the year on average, producing a signiﬁcant socio-
economic burden on the patients and their family
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OBJECTIVES: Topical steroids are the corner-stone of
current treatment for atopic dermatitis (AD), a chronic
ﬂuctuating inﬂammatory skin disease. However, steroids
carry a risk of local and systemic side effects limiting their
long term use and effectiveness. The objective was to
assess the incremental cost-effectiveness ratio (ICER) of
the new topical immunomodulator Tacrolimus in moder-
ate to severe AD. Tacrolimus has shown signiﬁcant clin-
ical improvement, maintained with long term intermittent
treatment up to four years. METHODS: A Markov
model was developed in MS-Excel. Model health states
represent severe, moderate, mild, and virtually cured AD
as deﬁned by the Eczema Area and Severity Index (EASI).
Based on prevalence data, 82% start with moderate, 18%
with severe AD. The model simulates monthly severity
ﬂuctuations. Transitions among health states were calcu-
lated from two 1-year observational trials (Tacrolimus 
n = 93, current care n = 120). Tacrolimus consumption
was obtained from the clinical trial, other resource utili-
sation from a two-round Delphi consensus panel (n = 8).
Unit costs from the Belgian health care payers perspective
were applied. Effects are expressed in “disease controlled
days”, deﬁned as days with mild or virtually cured AD.
The time horizon was from 1 (basecase) to 3 years.
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RESULTS: By the end of the ﬁrst year, Tacrolimus
increases the number of ‘disease controlled days’ with 59
days at an IC of €60, implying an ICER of 1€/disease con-
trolled day. Better ICERs are obtained in severe AD, when
taking into account UV light therapy costs in the steroid
arm, currently not reimbursed in Belgium. Due to the long
term clinical improvement, the ICER decreases with treat-
ment duration and Tacrolimus ointment is estimated to
become cost-saving as from 2 years treatment duration.
CONCLUSION: Tacrolimus is a cost-effective treatment
for moderate to severe AD, providing potential savings to 
the health care system during long term maintenance
treatment.
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THE COST-UTILITY OF
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(DOVOBET) OINTMENT IN THE TREATMENT OF
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OBJECTIVES: To evaluate the cost and utility of cal-
cipotriol/bethamethasone (Dovobet) compared to cal-
cipotriol (Dovonex) in the treatment of psoriasis vulgaris.
METHODS: A four-state Markov model was designed to
estimate the cost and utilities associated with psoriasis
treatment over a full year. The model consists of four
mutually exclusive health states: Controlled psoriasis, and
three states of uncontrolled psoriasis: Initial treatment,
subsequent treatment, and no treatment. Various sources
were used to estimate the parameters of the model, but
the primary source for utility scores and transition prob-
abilities was an international phase III trial, estimating
efﬁcacy and the quality of life for 737 patients ran-
domised to one of four different treatment options.
Among the treatment options were calcipotriol/
bethamethasone (Dovobet) once daily and the currently
most frequently prescribed topical antipsoriatic in the
UK, calcipotriol (Dovonex). RESULTS: In the baseline
model, the average annual cost to the NHS associated
with treatment of a psoriasis patient with calcipotriol/
bethamethasone (Dovobet) once daily amounted to
£64.7. The cost of calcipotriol twice-daily treatment in
the same period would amount to £120.3. In terms 
of number of QALYs gained in a year, calcipotriol/
bethamethasone (Dovobet) once daily patients on average
accumulated 0.7719 QALYs, compared to calcipotriol
twice daily patients who accumulated only 0.7599
QALYs. Thus, in the baseline model treatment with cal-
cipotriol/bethamethasone (Dovobet) twice daily is both
less costly and more effective than the current standard
therapy of calcipotriol twice daily. These results were
robust to extensive sensitivity analysis of important
assumptions. CONCLUSION: Looking at a full year of
treatment, the cost-utility analysis showed that cal-
cipotriol/bethamethasone (Dovobet) once daily was both
less expensive and yielded more QALYs than the current
standard therapy (calcipotriol).
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Atopic dermatitis is considered in modern society to be a
disease leading to large expenses of the state, person and
family. OBJECTIVE: Pharmacoeconomic analysis of
family expenses and losses connected with child’s atopic
dermatitis. METHODS: cost and expenses analysis of the
disease was conducted with account of expenses on phar-
macotherapy, hospital and ambulance treatment, disable-
ment pensions, temporary disability of parents and
evaluation of the disease inﬂuence on the standard of life
of the child and the whole family. In 2000–2003 we have
conducted polling of families with children having atopic
dermatitis, analysis of ambulatory cards and case histo-
ries in Vladivostok Children’s Municipal Clinic Hospital.
Also, life standard questionnaires were ﬁlled in.
RESULTS: Family expenses on the child’s disease treat-
ment in 2000 were 9658.9 rubles ($311.5), in 2001—
12142.1 rubles ($379), in 2002—13400 rubles ($446),
which made from 9.6 to 13.4% of family annual income.
The largest speciﬁc weight of expenses (36.1%) was
shown by drugs purchase: in 2000—3486.8 rubles
($112), in 2001—4383.2 ($136), 2002—4837.4 rubles
($161). In 2000 atopic dermatitis caused hospitalization
of the child in average in 1.54 ± 0.2 cases in a year, period
of treatment 15.62 ± 1.02 days. In 2002 share of expenses
on basis antiinﬂammatory therapy and consultations 
of allergist and dermatologist increased, while number of
hospitalization cases reduced to 1.01 ± 0.1, duration of
hospitalization reduced down to 10.37 ± 0.94 days per
one child in average during a year. Atopic dermatitis
detected decrease in life quality not only of the child but
also of the family as a whole. CONCLUSIONS: Effective
pharmacotherapy and observance of hypoallergic every
day life regulations led to improvement of children life
quality, reduced expenses on hospital assistance, tempo-
rary disability and disablement but increased the burden
of family expenses on drugs.
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